Atypical Hemolytic Uremic Syndrome (aHUS) Overview

Save information for later
Sign Up

Learn About Atypical Hemolytic Uremic Syndrome (aHUS)

What is the definition of Atypical Hemolytic Uremic Syndrome (aHUS)?
Atypical hemolytic uremic syndrome is a very rare disease that causes anemia due to red blood cell destruction, a low platelet count, blood clots, and acute kidney failure.
What are the symptoms of Atypical Hemolytic Uremic Syndrome (aHUS)?
Symptoms of atypical hemolytic uremic syndrome include a sudden onset, malaise, fatigue, lethargy, irritability, anemia, a low platelet count, acute kidney failure, high blood pressure, reduced blood flow and/or small blood clots in blood vessels, headaches, seizures, organ damage and failure, an enlarged heart, heart attack, gastrointestinal bleeding, swelling in the lungs, double vision, facial paralysis, stroke, and coma.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Atypical Hemolytic Uremic Syndrome (aHUS)?
Treatments for atypical hemolytic uremic syndrome include supportive care; nutritional therapy; blood transfusions; peritoneal dialysis or hemodialysis; plasma therapy; plasma exchange; medications, such as vasodilators, eculizumab, ravulizumab-cwvz, and immunosuppressants; and kidney transplantation.
Who are the top Atypical Hemolytic Uremic Syndrome (aHUS) Local Doctors?
Dr. Saloni H. Tanna
Hematology Oncology | Oncology | Hematology
Dr. Saloni H. Tanna
Hematology Oncology | Oncology | Hematology

Northeast Georgia Diagnostic Associates And Clinic, LLC

1240 Jesse Jewell Pkwy Se, Suite 500, 
Gainesville, GA 
 (90.4 mi)
770-536-9864
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saloni Tanna is a Hematologist Oncology specialist and an Oncologist in Gainesville, Georgia. Dr. Tanna and is rated as an Experienced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). Her top areas of expertise are Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Iron Deficiency Anemia. Dr. Tanna is currently accepting new patients.

Dr. Albert T. Quiery
Hematology | Transfusion Medicine
Dr. Albert T. Quiery
Hematology | Transfusion Medicine

University Health System, Inc.

1926 Alcoa Hwy, Suite 410, 
Knoxville, TN 
 (50.0 mi)
865-305-6333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Albert Quiery is a Hematologist and a Transfusion Medicine provider in Knoxville, Tennessee. Dr. Quiery and is rated as an Advanced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Sickle Cell Disease, Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Schnitzler Syndrome, and Bone Marrow Aspiration. Dr. Quiery is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. William B. Donnellan
Hematology Oncology | Hematology | Oncology
Dr. William B. Donnellan
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

1208 Pointe Centre Dr, Suite 110, 
Chattanooga, TN 
 (44.8 mi)
423-266-4764
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Donnellan is a Hematologist Oncology specialist and a Hematologist in Chattanooga, Tennessee. Dr. Donnellan and is rated as an Experienced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Donnellan is currently accepting new patients.

View All Doctors
What are the latest Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trials?
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Patients with Atypical Hemolytic Uremic Syndrome
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Adult and adolescent participants with atypical hemolytic uremic syndrome
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

View All Clinical Trials